Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

about

HEDD: the human epigenetic drug database Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.

P2860

Q28818364-862E7527-CF59-4007-9106-57914E40CABC Q37711782-843EFB9B-831B-4C7C-A9C0-A998DE64A30E Q39009379-1DBBA974-F8C6-4E29-90CC-5329708323BA

P2860

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q38752460

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

@en

type

Item

label

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

@en

prefLabel

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

@en

P1476

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

@en

P2093

Christan M Thomas

http://www.w3.org/2001/XMLSchema#string

Peter Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.

Histone deacetylase inhibitors in cancer therapy.

Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.

The role of histone deacetylases (HDACs) in human cancer.

P304

143-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155216634178

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26921086

http://www.w3.org/2001/XMLSchema#string

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

about

P2860

P2860

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698